Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M6620 (VX-970) and Gemcitabine in Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT02595892Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2016
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of berzosertib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Started Aug 2016; status: active, not recruiting.
02
Drugs
berzosertib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02595892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02595892.